Drugs / Iclepertin
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 met primary | ||||||
| Phase 1 | NCT06070597 | Jan → Jun 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05731895 | Mar → Dec 2023 | liver disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05613777 | Nov 2022 → Oct 2023 | — | Boehringer Ingelheim | Completed | Met primary |
| Phase 1 | NCT05258110 | Mar → May 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 34 trials · 3 missed | ||||||
| Phase 3 | NCT05211947 | Mar 2022 → Feb 2025 | schizophrenia | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 3 | NCT04846868 | Sep 2021 → Sep 2024 | schizophrenia | Boehringer Ingelheim | Completed | Missed primary |
| Phase 3 | NCT04846881 | Aug 2021 → Oct 2024 | schizophrenia | Boehringer Ingelheim | Completed | Missed primary |
| Phase 3 | NCT04860830 | Aug 2021 → Oct 2024 | schizophrenia | Boehringer Ingelheim | Completed | Missed primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-09-14 | Boehringer Ingelheim | Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia prnewswire.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iclepertin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04860830 ↗ |
| Known as | BI 425809 | “iclepertin (BI 425809)” NCT05258110 ↗ |
| Action | Inhibit | “CONNEX programme investigated the efficacy and safety of iclepertin, a glycine transporter-1 (GlyT1) inhibitor, for the treatment of CIAS.” PMID 41233083 ↗ Dec 2025 |
| Route | Oral | “Patients with schizophrenia took orally once a day one 10 milligram (mg) tablet of iclepertin.” NCT04846868 ↗ |